The FDA's fast track designation aims to expedite ITM-94's development for diagnosing clear cell renal cell carcinoma. The ...

DPI-4452 targets CAIX in tumors, offering noninvasive diagnostic potential for ccRCC with favorable tolerability. The agent is part of a theranostic pair wi ...

ITM-94 forms a theranostic pair with therapeutic candidate ITM-91, targeting carbonic anhydrase IX (CAIX) in clear cell renal cell carcinoma ...

A new study led by investigators from the UCLA Health Jonsson Comprehensive Cancer Center has demonstrated a new, non-invasive imaging technique can accurately detect clear-cell renal cell carcinoma, ...

An AI-based model for analyzing images appeared better able to predict ccRCC from CT-based images than a tumor size-based model was.

In a recent study, mean sensitivity was 85.5% and specificity 87% for detection of clear-cell renal cell carcinoma. (HealthDay News) — ⁸⁹Zr-labeled monoclonal antibody ([⁸⁹Zr]Zr-girentuximab) for ...

Today, Xencor management also became aware that an investment bank published takeaways from the abstract accepted for presentation at the conference, which is not publicly available via the conference ...

DENVER -- Planned treatment "holidays" can help lessen the toxicity burden of tyrosine kinase inhibitors (TKIs) for selected ...

During a live event, Moshe C. Ornstein, MD, MA, considered the trial design and outcomes of 2 trials of combination regimens ...

Current risk stratification models perform well in assessing recurrence risk in patients with non-clear cell renal cell carcinoma, researchers report.